<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref25">
 <label>25.</label>
 <mixed-citation publication-type="other">Inovio Pharmaceuticals. Inovio doses 1st subject in phase 1/2 clinical trial for vaccine against deadly MERS infection. 
  <ext-link ext-link-type="uri" xlink:href="http://ir.inovio.com/news-and-media/news/press-release-details/2018/Inovio-Doses-1st-Subject-in-Phase-12-Clinical-Trial--For-Vaccine-Against-Deadly-MERS-Infection/default.aspx" xmlns:xlink="http://www.w3.org/1999/xlink">http://ir.inovio.com/news-and-media/news/press-release-details/2018/Inovio-Doses-1st-Subject-in-Phase-12-Clinical-Trial--For-Vaccine-Against-Deadly-MERS-Infection/default.aspx</ext-link>. 
  <comment>[press release]</comment>
  <year>Published September 5, 2018</year>. Accessed September 10, 2019.
 </mixed-citation>
</ref>
